Loading
Led RTOG 0617, the trial that showed higher radiation doses do not help in stage III lung cancer and set today's 60 Gy standard.
Jeffrey Bradley was principal investigator of RTOG 0617, which unexpectedly found that escalating the dose to 74 Gy worsened survival compared with 60 Gy in stage III NSCLC, a result that fixed the standard dose and refocused the field on precision and cardiac sparing. He led the NRG proton-versus-photon lung trial and chairs thoracic radiotherapy committees in NRG Oncology.
Shares Proton therapy, Non-small-cell lung cancer and the tags radiotherapy, lung.
Shares Proton therapy, IMRT / IGRT (modern external beam), Non-small-cell lung cancer.
Shares IMRT / IGRT (modern external beam) and the tags radiotherapy, nrg-oncology.
Shares Non-small-cell lung cancer and the tags radiotherapy, lung.
Shares Non-small-cell lung cancer and the tags radiotherapy, lung.
Shares Proton therapy, IMRT / IGRT (modern external beam), Non-small-cell lung cancer.
Shares Proton therapy, IMRT / IGRT (modern external beam) and the tag radiotherapy.
Shares IMRT / IGRT (modern external beam) and the tag radiotherapy.